Relmada Therapeutics, Inc. (RLMD) DCF Valuation

Relmada Therapeutics, Inc. (RLMD) DCF Valuation
  • ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • ✓ Professional Design: Trusted, Industry-Standard Templates
  • ✓ Pre-Built For Quick And Efficient Use
  • ✓ No Expertise Is Needed; Easy To Follow

Relmada Therapeutics, Inc. (RLMD) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Looking to assess the intrinsic value of Relmada Therapeutics, Inc.? Our (RLMD) DCF Calculator integrates real-world data with comprehensive customization features, enabling you to adjust projections and enhance your investment choices.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 0 0 0 0 0 0 0 0 0
EBITDA -15.1 -59.5 -125.8 -157.0 4.9 .0 .0 .0 .0 .0
EBITDA, % 100 100 100 100 100 100 100 100 100 100
Depreciation .0 .0 .0 .0 103.7 .0 .0 .0 .0 .0
Depreciation, % 100 100 100 100 100 100 100 100 100 100
EBIT -15.1 -59.5 -125.8 -157.0 -98.8 .0 .0 .0 .0 .0
EBIT, % 100 100 100 100 100 100 100 100 100 100
Total Cash 116.4 117.1 211.9 148.3 96.3 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .1 .1 .5 .0
Account Receivables, % 100 100 100 100 100
Inventories .0 .9 11.3 4.0 .0 .0 .0 .0 .0 .0
Inventories, % 100 100 100 100 100 100 100 100 100 100
Accounts Payable .5 8.3 11.2 5.3 3.5 .0 .0 .0 .0 .0
Accounts Payable, % 100 100 100 100 100 100 100 100 100 100
Capital Expenditure .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Capital Expenditure, % 100 100 100 100 100 0 0 0 0 0
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -15.1 -59.5 -125.8 -157.0 -98.8 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -14.6 -52.6 -133.3 -156.1 7.7 -3.5 .0 .0 .0 .0
WACC, % 6.41 6.41 6.41 6.41 6.41 6.41 6.41 6.41 6.41 6.41
PV UFCF
SUM PV UFCF -3.3
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -3
Net Debt -4
Equity Value 1
Diluted Shares Outstanding, MM 30
Equity Value Per Share 0.03

What You Will Get

  • Accurate RLMD Financials: Access to historical and projected data for precise valuation.
  • Customizable Parameters: Adjust discount rates, tax assumptions, revenue projections, and capital expenses.
  • Real-Time Calculations: Intrinsic value and NPV are computed automatically.
  • Scenario Planning: Evaluate various scenarios to assess Relmada’s potential growth.
  • User-Friendly Interface: Designed for industry experts but easy for newcomers to navigate.

Key Features

  • Comprehensive Financial Data: Gain access to reliable pre-loaded historical figures and future forecasts for Relmada Therapeutics, Inc. (RLMD).
  • Adjustable Forecast Parameters: Modify highlighted fields such as WACC, growth rates, and profit margins to suit your analysis.
  • Real-Time Calculations: Experience automatic updates for DCF, Net Present Value (NPV), and cash flow evaluations.
  • User-Friendly Dashboard: Intuitive charts and summaries designed to help visualize your valuation outcomes.
  • Suitable for All Skill Levels: A streamlined and accessible format tailored for investors, CFOs, and consultants alike.

How It Works

  1. Download the Template: Gain immediate access to the Excel-based RLMD DCF Calculator.
  2. Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and additional parameters.
  3. Instant Calculations: The model automatically recalculates Relmada Therapeutics' intrinsic value.
  4. Test Scenarios: Experiment with various assumptions to assess potential changes in valuation.
  5. Analyze and Decide: Utilize the outcomes to inform your investment or financial strategies.

Why Choose This Calculator for Relmada Therapeutics, Inc. (RLMD)?

  • Accurate Data: Up-to-date financials for Relmada Therapeutics ensure dependable valuation outcomes.
  • Customizable: Tailor essential metrics such as growth rates, WACC, and tax rates to fit your forecasts.
  • Time-Saving: Built-in calculations save you the hassle of starting from the ground up.
  • Professional-Grade Tool: Crafted for investors, analysts, and consultants focused on Relmada Therapeutics.
  • User-Friendly: Clear layout and guided instructions make it accessible for all users.

Who Should Use This Product?

  • Professional Investors: Develop comprehensive and accurate valuation models for analyzing portfolios involving Relmada Therapeutics, Inc. (RLMD).
  • Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions within their organizations.
  • Consultants and Advisors: Deliver precise valuation insights for clients interested in Relmada Therapeutics, Inc. (RLMD).
  • Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling.
  • Biotech Enthusiasts: Gain insights into how biotech companies like Relmada Therapeutics, Inc. (RLMD) are valued in the financial markets.

What the Template Contains

  • Comprehensive DCF Model: Editable template with detailed valuation calculations tailored for Relmada Therapeutics, Inc. (RLMD).
  • Real-World Data: Relmada’s historical and projected financials preloaded for analysis.
  • Customizable Parameters: Adjust WACC, growth rates, and tax assumptions to test various scenarios.
  • Financial Statements: Full annual and quarterly breakdowns for in-depth insights into performance.
  • Key Ratios: Built-in analysis for profitability, efficiency, and leverage specific to Relmada Therapeutics, Inc. (RLMD).
  • Dashboard with Visual Outputs: Charts and tables providing clear, actionable results for stakeholders.

No products were found matching.